Rosemary Janas
Internal Medicine · Tewksbury, MANPI 1104978980
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 325 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 325 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$739
- Lilly USA, LLC$516
- Novo Nordisk$480
- Pfizer$376
- Amgen$342
- plus $3K from 35 others
What the payments were for
- Food & beverage$6,759100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,759 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 39 | $38,924 |
| EliquisApixaban | 14 | $13,543 |
| JardianceEmpagliflozin | 12 | $12,459 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $11,203 |
| XareltoRivaroxaban | 12 | $7,996 |
| Zolpidem Tartrate | 51 | $6,389 |
| Metoprolol Succinate | 174 | $3,507 |
| Atorvastatin Calcium | 239 | $3,074 |
| Simvastatin | 135 | $1,937 |
| Omeprazole | 101 | $1,928 |
| Memantine Hcl | 14 | $1,492 |
| Lisinopril | 151 | $1,319 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $1,230 |
| Levothyroxine Sodium | 92 | $952 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 41 | $724 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $480 | $38,92439 claims |
| PfizerEliquis | $376 | $13,54314 claims |
| Boehringer IngelheimJardiance | $174 | $12,45912 claims |
| AstraZenecaBreztri Aerosphere | $739 | $11,20313 claims |
| Johnson & JohnsonXarelto | $18 | $7,99612 claims |
| Almatica Pharma LLCSertraline Hcl | $24 | $49244 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Tewksbury
- David SchenkeinBoston$5M
- Alan GarberCambridge$4.9M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Sandra RichmanBrookline$1.4M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.